A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure - 16/08/11
, Willem J. Kop, PhD, Sue A. Thomas, RN, PhD, Scott Katzen, MD, Mark R. Vesely, MD, Nancy Greenberg, RN, Joanne Marshall, RN, Michelle Cines, RN, Stacey Minshall, RNRésumé |
Background |
Depression is frequently observed in patients with heart failure and is associated with poor quality of life and adverse prognosis. However, the prevalence of depression in heart failure could be overestimated because symptoms of depression overlap with those of heart failure. Similarly, the importance of depression may be overestimated if depression merely reflects worse heart failure. Because the response to depression treatment has not been evaluated in this patient population, we evaluated the efficacy of controlled-release paroxetine (paroxetine CR), a selective serotonin reuptake inhibitor, on depression and quality of life in chronic heart failure.
Methods |
A double-blind, randomized, placebo-controlled design was used to evaluate reductions in depression following 12 weeks of treatment with paroxetine CR (n = 14, age 62.1 ± 12.3 years) or placebo (n = 14, age = 61.9 ± 9.0 years). Patients with symptomatic congestive heart failure and a score of at least 10 on the Beck Depression Inventory (BDI) were eligible. Beck Depression Inventory was obtained at baseline and 4, 8, and 12 weeks of follow-up. Quality of life was assessed using the Medical Outcomes Study Short Form and the Minnesota Living with Heart Failure Questionnaire.
Results |
Controlled-release paroxetine resulted in significantly more recovery from depression (BDI <10) than placebo (69% vs 23%, P = .018) and resulted in lower continuous BDI scores throughout the intervention (P = .024). Controlled-release paroxetine was associated with higher general health levels compared with placebo on the Medical Outcomes Study 36-Item Short Form survey (38 ± 10 vs 30 ± 6, P = .016) at 12 weeks of follow-up. Reductions in depression were correlated with improvements in psychological aspects of quality of life (P < .05) but not with physical quality of life measures (P > .10).
Conclusion |
Antidepressant therapy with paroxetine CR results in significant reductions in depression among patients with heart failure. The reductions in depression with paroxetine CR are accompanied by improvements in psychological aspects of quality of life. Larger controlled trials are needed to further document the effectiveness of paroxetine CR and other selective serotonin reuptake inhibitors in patients with heart failure and to determine patient subgroups that are most likely to benefit from antidepressive interventions.
Le texte complet de cet article est disponible en PDF.Plan
| Supported by a grant from GlaxoSmithKline (King of Prussia, PA), the University of Maryland School of Medicine, and the Baltimore Veterans Administration Medical Center. |
Vol 153 - N° 5
P. 868-873 - mai 2007 Retour au numéro
Article précédent
- Exercise oscillatory breathing and increased ventilation to carbon dioxide production slope in heart failure: An unfavorable combination with high prognostic value
- Marco Guazzi, Ross Arena, Aniello Ascione, Massimo Piepoli, Maurizio D. Guazzi, on behalf of the “Gruppo di Studio Fisiologia dell'Esercizio, Cardiologia dello Sport e Riabilitazione Cardiovascolare” of the Italian Society of Cardiology
- Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease
- Paul Michael Grossman, Farrell Mendelsohn, Timothy D. Henry, James B. Hermiller, Marc Litt, Jorge F. Saucedo, Robert J. Weiss, David E. Kandzari, Neal Kleiman, R. David Anderson, Daniel Gottlieb, Ronald Karlsberg, Jeffery Snell, Krishna Rocha-Singh
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?